We are live on
!
Find out more
SCM
Scopia Capital Management Portfolio holdings
AUM
$112M
1-Year Est. Return
48.41%
This Fund
S&P 500
This Quarter
Est. Return
+14%
1 Year Est. Return
+48.41%
3 Year Est. Return
+58.7%
5 Year Est. Return
+80.15%
10 Year Est. Return
+533.22%
AUM
$6.32B
AUM Growth
+$1.48B
(+30%)
Cap. Flow
-$95.2M
Cap. Flow
% of AUM
-1.5%
Top 10 Holdings %
Top 10 Hldgs %
70.14%
Holding
41
New
6
Increased
12
Reduced
7
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Plains GP Holdings
PAGP
|
+$129M |
| 2 |
ISBC
Investors Bancorp, Inc.
ISBC
|
+$88.4M |
| 3 |
Equifax
EFX
|
+$69M |
| 4 |
WFT
Weatherford International plc
WFT
|
+$58.3M |
| 5 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$52.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
|
+$154M |
| 2 |
Conduent
CNDT
|
+$111M |
| 3 |
Antero Resources
AR
|
+$100M |
| 4 |
United Therapeutics
UTHR
|
+$91.5M |
| 5 |
Ligand Pharmaceuticals
LGND
|
+$88.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.97% |
| 2 | Miscellaneous | 16.86% |
| 3 | Industrials | 14.9% |
| 4 | Communication Services | 14.1% |
| 5 | Real Estate | 13.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AUD
26
DELISTED
Audacy, Inc.
AUD
| $25.8M | 0.41% |
2,250,082
+1,002,130
| +80% | +$10.2M |
|
27
PTC Therapeutics
PTCT
$5.48B
| $23.9M | 0.38% |
+1,194,129
| New | +$23.4M |
|
|
NDRM
28
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $7.99M | 0.13% |
205,358
-4,178,000
| -95% | -$154M |
|
29
Fossil Group
FOSL
$298M
| $3.69M | 0.06% |
395,925
| – | – |
|
30
MannKind Corp
MNKD
$1.14B
| $2.13M | 0.03% |
982,930
| – | – |
|
31
Prospect Capital
PSEC
$1.14B
| $700K | 0.01% |
104,194
| – | – |
|
32
American Superconductor
AMSC
$1.34B
| $89K | ﹤0.01% |
19,610
| – | – |
|
33
Antero Midstream
AM
$10.1B
| – | – |
-935,053
| Closed | -$20.6M |
|
|
34
Antero Resources
AR
$11.9B
| – | – |
-4,643,955
| Closed | -$100M |
|
35
CALL
Baidu
BIDU
$30.8B
| – | – |
-400,000
| Closed | -$71.5M |
|
|
36
Conduent
CNDT
$255M
| – | – |
-6,979,221
| Closed | -$111M |
|
|
37
Ligand Pharmaceuticals
LGND
$5.52B
| – | – |
-1,167,886
| Closed | -$88.4M |
|
|
MRSN
38
DELISTED
Mersana Therapeutics
MRSN
| – | – |
-8,145
| Closed | -$2.85M |
|
|
ACH
39
Accendra Health
ACH
$85.4M
| – | – |
-387,901
| Closed | -$12.5M |
|
|
40
United Therapeutics
UTHR
$21.5B
| – | – |
-705,003
| Closed | -$91.5M |
|
|
I
41
DELISTED
INTELSAT S. A.
I
| – | – |
-1,487,257
| Closed | -$4.55M |
|
Similar funds
SWM
TFS
WAM
CS
BU
TBFA
VDC
RQS
Scopia Capital Management's Q3 2017 Portfolio in Review
As of Q3 2017, Scopia Capital Management held 41 positions worth $6.32B, up 30% from $4.85B the previous quarter. Its ten largest holdings account for 70% of the portfolio.
Scopia Capital Management's Q3 2017 filing shows 6 new, 12 increased, 7 reduced and 9 closed positions. Its largest new stake was Plains GP Holdings: 5,415,491 shares worth $118M. The largest sale was NeuroDerm Ltd. Ordinary Shares, an estimated $154M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, down from 28% a quarter earlier, followed by Miscellaneous and Industrials.
- Scopia Capital Management's largest Q3 2017 buy was Plains GP Holdings: 5,415,491 shares worth $118M.
- Scopia Capital Management added most to GW Pharmaceuticals Plc American Depositary Shares in Q3 2017, an estimated $52.8M increase.
- Scopia Capital Management's biggest Q3 2017 reduction was NeuroDerm Ltd. Ordinary Shares, cutting an estimated $154M.
- Scopia Capital Management fully exited Conduent in Q3 2017, selling an estimated $111M.
- Scopia Capital Management's ten largest holdings make up 70% of its $6.32B portfolio in Q3 2017.
- Scopia Capital Management opened 6 new positions and closed 9 in Q3 2017.
- Scopia Capital Management's portfolio value rose 30% quarter-over-quarter to $6.32B.
Based on Scopia Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.